ATE185971T1 - Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen - Google Patents

Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen

Info

Publication number
ATE185971T1
ATE185971T1 AT97250127T AT97250127T ATE185971T1 AT E185971 T1 ATE185971 T1 AT E185971T1 AT 97250127 T AT97250127 T AT 97250127T AT 97250127 T AT97250127 T AT 97250127T AT E185971 T1 ATE185971 T1 AT E185971T1
Authority
AT
Austria
Prior art keywords
men
treatment
combination preparation
hypogonadal
hypophysis diseases
Prior art date
Application number
AT97250127T
Other languages
English (en)
Inventor
Michael Prof Oettel
Siegfried Dr Golbs
Michael Prof Dittel
Carsten Dr Timpe
Thomas Dr Graeser
Doris Dr Huebler
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7794048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE185971(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Application granted granted Critical
Publication of ATE185971T1 publication Critical patent/ATE185971T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97250127T 1996-05-02 1997-04-19 Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen ATE185971T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19619045A DE19619045C1 (de) 1996-05-02 1996-05-02 Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen

Publications (1)

Publication Number Publication Date
ATE185971T1 true ATE185971T1 (de) 1999-11-15

Family

ID=7794048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97250127T ATE185971T1 (de) 1996-05-02 1997-04-19 Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen

Country Status (5)

Country Link
US (1) US5855905A (de)
EP (1) EP0804926B1 (de)
AT (1) ATE185971T1 (de)
CL (1) CL2004000675A1 (de)
DE (2) DE19619045C1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP3694326B2 (ja) * 1998-03-23 2005-09-14 三菱電機株式会社 データ処理装置
GB9807809D0 (en) * 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
US6645954B2 (en) 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
DE19831263A1 (de) * 1998-07-11 2000-01-13 Lohmann Therapie Syst Lts Darreichungsform
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CZ20013912A3 (cs) * 1999-05-04 2002-05-15 Strakan Limited Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7025979B2 (en) 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone
CA2402524C (en) * 2000-03-31 2009-11-17 Richard P. Blye Methods of making and using 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxy-4-estren-3-one 17.beta.-trans-4-n-butylcyclohexane carboxylate and 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestr-4-en-3-one 17-undecanoate
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
US20060142257A1 (en) * 2001-01-19 2006-06-29 Eberhard Nieschlag Male contraceptive formulation comprising norethisterone
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
AU2003206434A1 (en) * 2002-02-15 2003-09-04 Pantarhei Bioscience B.V. Pulmonary administration of 6-alpha-alkylated testosterone derivatives for androgen replacement therapy
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
RU2383346C2 (ru) * 2007-10-30 2010-03-10 Андрей Иванович Гомжин Способ лечения больных гипогонадизмом с синдромом обструктивного апноэ сна
EP2257220B1 (de) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Fussbetätigte multifunktionssteuerung für bildgebungssystem
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA2818491A1 (en) * 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US10471007B2 (en) 2016-12-16 2019-11-12 Jeffrey R Olynyk Sublingual therapeutic solutions and methods
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CN119055659A (zh) * 2024-09-03 2024-12-03 南通大学 17α雌二醇或其化学修饰衍生物在制备预防和/或治疗男性性腺功能低下的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4473564A (en) * 1983-07-12 1984-09-25 Akzo N.V. 19-Thio-androstane derivatives
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
EP0680327B1 (de) * 1993-01-19 2004-09-15 Endorecherche Inc. Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron

Also Published As

Publication number Publication date
DE19619045C1 (de) 1997-11-13
US5855905A (en) 1999-01-05
CL2004000675A1 (es) 2005-01-07
DE59700608D1 (de) 1999-12-02
EP0804926A1 (de) 1997-11-05
EP0804926B1 (de) 1999-10-27

Similar Documents

Publication Publication Date Title
DE59700608D1 (de) Kombinationspräparat zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
FR12C0004I1 (de)
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
UA43378C2 (uk) Композиція для лікування респіраторного дистрес-синдрому новонароджених та респіраторного дистрес-синдрому дорослих
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
PL328858A1 (en) Immunogenous peptides
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
EP0846466A3 (de) Zusammensetzungen zur Behandlung von Rheumatoiden arthritis Krankheiten
DK0938326T3 (da) Syntetiske phosphopeptider til behandling af knoglesygdomme
MY138883A (en) Use of asiatic acid for treatment of cencer
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE229338T1 (de) 2',2'-difluornucleoside zur immunosuppressiven therapie und kombinationspräparate
AR016981A2 (es) Polipeptidos sinteticos
GB9805616D0 (en) Extracting particles produced by the treating of human or animal nails
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
TR200200278T2 (tr) Kalsilitik bileşimler
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee